Clinical evidence indicates that EGFR overexpression is linked to poorer prognosis and adverse outcomes in aggressive TNBC patients, while IGF-IR is overexpressed in varying degrees across breast cancer subtypes [20,21]. This evidence concerns the gene IGF1R and breast cancer.